Shots: The P-lll RUXCOVID study involves assessing Ruxolitinib (5mg, bid) + SoC therapy vs PBO + SoC therapy in 432 patients aged ≥12 yrs. in a ratio (2:1) hospitalized for […]readmore
Tags : RUXCOVID Study
Shots: The P-III RUXCOVID study involves assessing of ruxolitinib (5mg, bid) + SoC vs PBO + SoC in 400 patients in a ratio (2:1) aged ≥12 yrs. with COVID-19 associated […]readmore